Acquired generalized lipodystrophy under immune checkpoint inhibition.

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Immune checkpoint inhibitors, particularly anti-programmed cell death (PD)-1 antibodies, are standard cancer treatments.
• Immune-related adverse events (irAEs) are common, with cutaneous and endocrine irAEs frequently observed.

Observation:

• A patient treated with pembrolizumab for metastatic melanoma developed severe acquired generalized lipodystrophy.
• This condition presented as subcutaneous fat loss, central obesity, insulin resistance, and decreased leptin levels.
• Histological analysis confirmed fat cell destruction with inflammation.

Findings:

• Anti-PD-1 therapy can induce acquired generalized lipodystrophy.
• This irAE is associated with significant and potentially persistent metabolic complications.
• Differential diagnoses, including genetic and autoimmune conditions, were excluded.

Implications:

• Clinicians must recognize acquired generalized lipodystrophy as a potential irAE of anti-PD-1 therapy.
• Increased awareness is crucial given the widespread use of these immunotherapies.
• Understanding the full spectrum of irAEs is vital for patient management and monitoring.